Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders
Investing considerably in production capacity for medical device packaging at its Rohrdorf and Halle sites in Germany
Lupin updates on shipment of Mirabegron ER Tablets
These devices instantly detect various arrhythmias, including atrial fibrillation (Afib), bradycardia, tachycardia, and more
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
Investing in Malaysia's largest clinic operator to expand the healthcare business
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
Subscribe To Our Newsletter & Stay Updated
